Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-8895a in Subjects With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2019
Price : $35 *
At a glance
- Drugs DS 8895 (Primary)
- Indications Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium
- 10 Apr 2017 Status changed from active, no longer recruiting to completed.
- 13 Feb 2017 Status changed from recruiting to active, no longer recruiting.